Harlequin
A CBD-dominant strain with mild intoxication and a stabilized 5:2 cannabinoid ratio.
Growing, buying or possessing cannabis and seeds is legal only in some places. Check the law where you live before acting on this information.
Harlequin is one of the first widely propagated high-CBD strains to reach the legal market, and that matters: it proved you could breed for low THC and high CBD without decades of back-crossing. But the lineage story is folklore, the 'sativa' label predicts nothing about how it feels, and there's no clinical trial on Harlequin itself. What you're actually buying is reliable, mild flower. That's useful. Just don't expect miracles.
Overview
Harlequin is a CBD-dominant cannabis cultivar that emerged in Northern California in the late 2000s during the early wave of laboratory-identified high-CBD plants. It typically tests with significantly more CBD than THC—commonly cited near a 5:2 ratio—resulting in mild intoxication even at substantial doses.
Alongside strains like Cannatonic and ACDC, Harlequin proved that selective breeding could re-establish the CBD-dominant chemotype that had largely disappeared from illicit markets during decades of THC-focused selection Anecdote. While not definitively 'the first' high-CBD strain available, Harlequin became one of the earliest widely propagated examples and remains a standard reference point in high-CBD breeding [1].
Chemistry
Cannabinoids.
Harlequin is classified as a CBD-dominant or Type II/III chemotype Strong evidence[1]. Published and lab-reported cannabinoid figures typically range from 8–16% CBD and 4–7% THC. The CBD:THC ratio is generally the more stable trait across batches; absolute percentages vary by phenotype, growing conditions, and testing laboratory Anecdote.
Terpenes.
Terpene profiles reported by commercial cannabis labs for Harlequin show considerable variation, with myrcene, β-caryophyllene, and α-pinene each appearing as dominant terpenes depending on the specific sample and grower Weak / limited. There is no single, standardized Harlequin terpene fingerprint—claims to identify one are marketing rather than verifiable fact Disputed.
The notion that a terpene like myrcene, at any threshold concentration, reliably predicts sedation or 'indica-like' effects is not supported by controlled human research. See The Myrcene 0.5% Threshold and The Indica/Sativa Myth for deeper discussion.
Reported Effects
User reports consistently describe Harlequin as clear-headed, mildly relaxing, and only lightly intoxicating—a profile consistent with what would be expected from a low-THC, high-CBD chemotype Anecdote. Many users report suitability for daytime or functional use.
CBD has been shown in controlled laboratory and clinical studies to attenuate some of the intoxicating and anxiogenic (anxiety-promoting) effects of THC, though the magnitude and precise conditions of that modulation remain debated among researchers Disputed[2][3].
Important caveat: There is no strain-specific clinical trial data for Harlequin. Cannabis research on CBD and THC uses purified or standardized extracts in controlled doses, not flower from a particular cultivar. Any claim that 'Harlequin treats anxiety,' 'Harlequin reduces inflammation,' or 'Harlequin helps with pain' is extrapolation from general CBD/THC pharmacology research, not evidence specific to this plant No data.
What is reasonable to expect: a functional, mildly pleasant experience with substantially lower risk of the racing heart, paranoia, or cognitive overwhelm that some people report from higher-THC flower.
Lineage (Disputed)
The most commonly repeated lineage is:
Colombian Gold × Nepali Indica × Thai × Swiss Sativa
This lineage is frequently attributed to a California grower known as the House of David Collective, credited with stabilizing Harlequin around 2009 Anecdote[1].
This lineage has never been confirmed by any verifiable breeder documentation, seed bank record, or genetic laboratory analysis Disputed. The term 'Swiss Sativa' in particular is geographically vague and lacks specificity. Broader cannabis research has demonstrated that strain names are unreliable indicators of actual genetic relationships; the same marketed name can refer to genetically distinct plants from different sources Strong evidence[4].
What is reasonably well-established: Harlequin was identified and stabilized in Northern California in the late 2000s as part of the early, deliberate high-CBD cultivar movement. The exact parental cross should be treated as oral history rather than established fact, and phenotypic variation in Harlequin across growers suggests either a degree of genetic heterogeneity or considerable environmental influence on expressed ratios.
Cultivation Basics
Harlequin is generally reported by growers as moderately straightforward to cultivate, with a sativa-leaning morphology—taller plants, longer internodes between nodes, and a more open bud structure compared to compact indicas Anecdote.
Flowering time: Typically 8–9 weeks indoors Anecdote.
Yield: Moderate; not known as a heavy producer Anecdote.
Key cultivation notes:
- Phenotype variability. Because Harlequin has been propagated widely from seed and clones of mixed provenance, CBD and THC expression varies noticeably between individual plants and grower sources. If a specific CBD level matters to your use case (e.g., in a regulated market or for personal dosing), lab testing the final flower is essential Anecdote.
- Mold susceptibility. Reported as average; the open flower structure aids airflow, but the extended flowering window (8–9 weeks) can present challenges in humid climates Anecdote.
- Nutrient demand. Grower reports describe Harlequin as a light-to-moderate feeder relative to modern high-THC hybrids, though no controlled comparison data exists Anecdote.
No peer-reviewed cultivation studies specific to Harlequin are available; all guidance here reflects practitioner consensus.
Marketing vs. Reality
What marketing typically claims:
- Harlequin is a 'sativa' that delivers focused, clear-headed relief from anxiety, pain, and inflammation.
- It has a unique, signature terpene profile that explains its effects.
- Its lineage is well-documented and stable.
What the evidence actually shows:
- The 'sativa' label describes morphology (tall plant, open structure), not a reliable predictor of subjective effect. See The Indica/Sativa Myth Disputed[5].
- Claimed effects on anxiety, pain, or inflammation are extrapolated from general CBD and cannabinoid research, not from trials on Harlequin flower itself No data.
- Harlequin does not have a single, stable terpene profile; profiles vary meaningfully across growers and batches Weak / limited.
- The lineage story, while widely repeated, is undocumented folklore Disputed.
What is genuinely useful and true:
Harlequin is a reliably CBD-dominant flower with a ratio that makes it a practical choice if you seek the experience of cannabis without strong intoxication. Before the rediscovery and cultivation of high-CBD plants in the 2000s, this product category barely existed in the illicit market. That functional distinction—low-THC, high-CBD flower you can consume as flower—is real and meaningful, even if the mystique surrounding Harlequin specifically is partly marketing.
Frequently Asked Questions
Is Harlequin an indica or sativa?
Harlequin displays sativa-like morphology (tall, open structure) but that label tells you little about actual effects. See The Indica/Sativa Myth for why the distinction is botanically vague and poor at predicting how any strain will feel. The chemotype (CBD-dominant) is far more predictive of effect than the sativa label.
How much THC does Harlequin have?
Typically 4–7% THC, paired with 8–16% CBD, for a ratio around 5:2. Because Harlequin is propagated from seed and clones of varying provenance, THC and CBD levels vary across sources. Lab testing a specific batch is the only way to know the actual content.
How long does Harlequin take to flower?
Indoors, typically 8–9 weeks. Outdoor flowering time depends on your climate and latitude; expect a standard late-September to October finish in most Northern Hemisphere regions.
Who bred Harlequin?
The commonly cited answer is the House of David Collective in California, c. 2009. However, this credit and the reported lineage (Colombian Gold × Nepali Indica × Thai × Swiss Sativa) are unverified oral history. No documented breeder record or genetic confirmation of the parentage exists.
Sources
- Reported Leafly Cannabis Strain Database. Harlequin Strain Information.
- Peer-reviewed Freeman, A. M., et al. (2019). How does cannabidiol (CBD) influence the acute effects of delta-9-tetrahydrocannabinol (THC) in humans? A systematic review. Neuroscience & Biobehavioral Reviews, 107, 696–712.
- Peer-reviewed Russo, E. B. (2011). Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. British Journal of Pharmacology, 163(7), 1344–1364.
- Peer-reviewed Sawler, J., Stout, J. M., Gardner, K. M., Hudson, D., Vidmar, J., Butler, L., Page, J. E., & Myles, S. (2015). The Genetic Structure of Marijuana and Hemp. PLOS ONE, 10(8), e0133292.
- Peer-reviewed Piomelli, D., & Russo, E. B. (2016). The Cannabis sativa Versus Cannabis indica Debate: An Interview with Ethan Russo, MD. Cannabis and Cannabinoid Research, 1(1), 44–46.
How this page was made
Generation history
Drafted with AI assistance and checked by a separate automated fact-check pass. Not every article has been read by a person. See how articles are made.
Related
- The Indica/Sativa Myth — The popular classification system contradicts genetics, chemistry, and controlled research...
- The Myrcene 0.5% Threshold — A viral cannabis rule with no peer-reviewed evidence behind it.